Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs-Reference-Cited by-同舟云学术

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti‐Inflammatory Drugs

Author:

Theken Katherine N.¹,Lee Craig R.²,Gong Li³,Caudle Kelly E.⁴,Formea Christine M.⁵⁶,Gaedigk Andrea⁷⁸,Klein Teri E.³,Agúndez José A.G.⁹,Grosser Tilo¹

Affiliation:

1. Institute for Translational Medicine and Therapeutics Perelman School of Medicine University of Pennsylvania Philadelphia Pennsylvania USA

2. Division of Pharmacotherapy and Experimental Therapeutics Eshelman School of Pharmacy University of North Carolina Chapel Hill North Carolina USA

3. Department of Biomedical Data Science and Department of Medicine Stanford University Stanford California USA

4. Department of Pharmaceutical Sciences St. Jude Children’s Research Hospital Memphis Tennessee USA

5. Department of Pharmacy and Center for Individualized Medicine Mayo Clinic Rochester Minnesota USA

6. Department of Pharmacy and Intermountain Precision Genomics Intermountain Healthcare Salt Lake City Utah USA

7. Division of Clinical Pharmacology Toxicology & Therapeutic Innovation Children's Mercy Kansas City Kansas City Missouri USA

8. School of Medicine University of Missouri-Kansas City Kansas City Missouri USA

9. University Institute of Molecular Pathology BiomarkersUEx. ARADyAL Instituto de Salud Carlos IIICáceres Spain

Funder

National Institutes of Health

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

Reference40 articles.

1. Clinical Pharmacogenetics Implementation Consortium (CPIC).CPIC Guideline for NSAIDs based on CYP2C9 genotype.

2. Pharmacogenomics Knowledgebase (PharmGKB).Gene‐specific Information Tables for CYP2C9.

Cited by 223 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献